Theriva reports VCN-01 improved survival in Phase 2b pancreatic cancer trial

Filed April 17, 2026 · Period ending April 17, 2026 · ~1 min read

Key Changes

• high

  VCN-01 combined with chemotherapy improved both overall survival and progression-free survival versus chemotherapy alone in metastatic pancreatic cancer patients. Late separation of survival curves suggests immune-mediated mechanism.

  Item 7.01: VIRAGE Trial Results verify on EDGAR →
• high

  Tumor responses with VCN-01 combination were later-emerging but stronger and more durable than chemotherapy alone, consistent with immunotherapy patterns and suggesting sustained clinical benefit.

  Item 7.01: Treatment Response verify on EDGAR →
• medium

  Patients receiving a second dose of VCN-01 showed greater survival benefit than single-dose patients, informing optimal dosing strategy for future trials and potential commercial use.

  Item 7.01: Dosing Analysis verify on EDGAR →